Onderneming Eiger BioPharmaceuticals, Inc.
Aandelen
EIGR
US28249U2042
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,67 USD | -12,17% | +11,72% | -60,36% |
Vakgebied
Aantal werknemers: 25
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Therapies
100,0
%
| 13 | 100,0 % | 16 | 100,0 % | +16,98% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States, Ireland and United Kingdom
100,0
%
| 13 | 100,0 % | 16 | 100,0 % | +16,98% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Director of Finance/CFO | 58 | 13-04-23 | |
James Vollins
CMP | Compliance Officer | 55 | 13-04-23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Chief Tech/Sci/R&D Officer | 57 | 18-04-22 | |
General Counsel | - | 01-04-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 18-07-22 | |
Thomas Dietz
CHM | Chairman | 60 | 22-03-16 |
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Amit Sachdev
BRD | Director/Board Member | 56 | 15-04-19 |
Evan Loh
BRD | Director/Board Member | 65 | 18-09-17 |
Kim Sablich
BRD | Director/Board Member | 55 | 23-04-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 480 797 | 1 306 238 ( 88,21 %) | 0 | 88,21 % |
Bedrijfsgegevens
Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard
94306-1543, Palo Alto
+650 272 6138
http://www.eigerbio.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-60,36% | 3,95 mln. | |
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |
- Beurs
- Aandelen
- Koers EIGR
- Onderneming Eiger BioPharmaceuticals, Inc.